Grifols (NASDAQ:GRFS) Upgraded to “Strong-Buy” at Berenberg Bank

Berenberg Bank upgraded shares of Grifols (NASDAQ:GRFS) to a strong-buy rating in a research note issued to investors on Tuesday, Zacks.com reports.

Grifols Price Performance

Shares of NASDAQ:GRFS opened at $8.77 on Tuesday. The company’s fifty day moving average price is $8.82 and its 200-day moving average price is $7.77. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.68 and a quick ratio of 0.80. The firm has a market capitalization of $6.03 billion, a price-to-earnings ratio of 8.68 and a beta of 0.50. Grifols has a one year low of $5.30 and a one year high of $12.15.

Grifols (NASDAQ:GRFS) last released its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21). The business had revenue of $1.96 billion during the quarter. On average, equities research analysts anticipate that Grifols will post 0.79 earnings per share for the current fiscal year.

Institutional Trading of Grifols

A number of hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC grew its position in Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 1,135 shares during the last quarter. Signaturefd LLC raised its position in Grifols by 66.2% in the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 2,153 shares during the period. AQR Capital Management LLC purchased a new position in Grifols in the 2nd quarter worth $89,000. Creative Planning lifted its stake in Grifols by 26.4% in the third quarter. Creative Planning now owns 17,319 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 3,614 shares during the last quarter. Finally, International Assets Investment Management LLC purchased a new stake in Grifols during the third quarter valued at about $1,700,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.